The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Lead- and drug-like compounds: the rule-of-five revolution
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Self-citationLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Self-citationMolecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
The Properties of Known Drugs. 1. Molecular Frameworks
Bemis, G. W., & Murcko, M. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9602928 · Cited by 2,482
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
Simple Selection Criteria for Drug-like Chemical Matter
Muegge, I., Heald, S. L., & Brittelli, D. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015507e · Cited by 1,315
Kelder, J., Grootenhuis, P. D. J., Bayada, D. M., Delbressine, L. P. C., & Ploemen, J.-P. (1999) · Pharmaceutical Research · doi:10.1023/a:1015040217741 · Cited by 813
Is There a Difference between Leads and Drugs? A Historical Perspective
Oprea, T. I., Davis, A. M., Teague, S. J., & Leeson, P. D. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010366a · Cited by 769
The Practice of Medicinal Chemistry
(2003) · Elsevier eBooks · doi:10.1016/b978-0-12-744481-9.x5000-4 · Cited by 702
Property distribution of drug-related chemical databases*
Oprea, T. I. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008130001697 · Cited by 628
Cited by
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
Newman, D. J., & Cragg, G. M. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01285 · Cited by 7,015
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Medicinal chemical properties of successful central nervous system drugs
Pajouhesh, H., & Lenz, G. R. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.541 · Cited by 1,535
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Current Contributions of Organofluorine Compounds to the Agrochemical Industry
Ogawa, Y., Tokunaga, E., Kobayashi, O., Hirai, K., & Shibata, N. (2020) · iScience · doi:10.1016/j.isci.2020.101467 · Cited by 1,253
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
Muratov, E. N., Bajorath, J., Sheridan, R. P., Tetko, I. V., Filimonov, D., Poroikov, V., Oprea, T. I., Baskin, I. I., Varnek, A., Roitberg, A., et al. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00098a · Cited by 913
Kurkov, S. V., & Loftsson, T. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.06.055 · Cited by 831
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Cyclodextrins: structure, physicochemical properties and pharmaceutical applications
Jansook, P., Ogawa, N., & Loftsson, T. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.11.018 · Cited by 811
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles
Wischke, C., & Schwendeman, S. P. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.042 · Cited by 790
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion
Su, R., Dong, L., Li, Y., Gao, M., Han, L., Wunderlich, M., Deng, X., Li, H., Huang, Y., Gao, L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.017 · Cited by 763
Principles for targeting RNA with drug-like small molecules
Warner, K. D., Hajdin, C. E., & Weeks, K. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.93 · Cited by 749
Dugasani, S., Pichika, M. R., Nadarajah, V. D., Balijepalli, M. K., Tandra, S., & Korlakunta, J. N. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.10.004 · Cited by 738
ToxCast Chemical Landscape: Paving the Road to 21st Century Toxicology
Richard, A. M., Judson, R. S., Houck, K. A., Grulke, C. M., Volarath, P., Thillainadarajah, I., Yang, C., Rathman, J., Martin, M. T., Wambaugh, J. F., et al. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00135 · Cited by 709
Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health
Salehi, B., Machin, L., Monzote, L., Sharifi-Rad, J., Ezzat, S. M., Salem, M. A., Merghany, R. M., El Mahdy, N. M., Kılıç, C. S., Sytar, O., et al. (2020) · ACS Omega · doi:10.1021/acsomega.0c01818 · Cited by 707
Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery
O’Shea, R., & Moser, H. E. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700967e · Cited by 689
Facts and fictions about polymorphism
Cruz-Cabeza, A. J., Reutzel-Edens, S. M., & Bernstein, J. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00227c · Cited by 678
Drug discovery and development: Role of basic biological research
Mohs, R. C., & Greig, N. H. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.005 · Cited by 673
Zhou, Y., Zhang, Y., Lian, X., Li, F., Wang, C., Zhu, F., Qiu, Y., & Chen, Y. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab953 · Cited by 665
Emerging therapeutic opportunities for integrin inhibitors
Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, R. G., & Hatley, R. J. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00284-4 · Cited by 540
The application of in silico drug-likeness predictions in pharmaceutical research
Tian, S., Wang, J., Li, Y., Li, D., Xu, L., & Hou, T. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.009 · Cited by 498
Deep Docking: A Deep Learning Platform for Augmentation of Structure Based Drug Discovery
Gentile, F., Agrawal, V., Hsing, M., Ton, A.-T., Ban, F., Norinder, U., Gleave, M. E., & Cherkasov, A. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00229 · Cited by 447
Orally Absorbed Cyclic Peptides
Nielsen, D. S., Shepherd, N. E., Xu, W., Lucke, A. J., Stoermer, M. J., & Fairlie, D. P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00838 · Cited by 445
Constraining Cyclic Peptides To Mimic Protein Structure Motifs
Hill, T. A., Shepherd, N. E., Diness, F., & Fairlie, D. P. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201401058 · Cited by 418
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Deacon, C. F. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0399-8 · Cited by 398
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A.-M., Choi, Y. H., & Tu, M.-J. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 395
Using the Golden Triangle to optimize clearance and oral absorption
Johnson, T. W., Dress, K. R., & Edwards, M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.045 · Cited by 392
Molecular modeling in drug discovery
Adelusi, T. I., Oyedele, A.-Q. K., Boyenle, I. D., Ogunlana, A. T., Adeyemi, R. O., Ukachi, C. D., Idris, M. O., Olaoba, O. T., Adedotun, I. O., Kolawole, O. E., et al. (2022) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2022.100880 · Cited by 387
Intestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
C, S., S., D. K., Ragunathan, V., Tiwari, P., A., S., & P, B. D. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1815584 · Cited by 375
Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
Dong, G., Ding, Y., He, S., & Sheng, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00895 · Cited by 369
Ten years of dengue drug discovery: Progress and prospects
Lim, S. P., Wang, Q.-Y., Noble, C. G., Chen, Y.-L., Dong, H., Zou, B., Yokokawa, F., Nilar, S., Smith, P., Beer, D., et al. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.013 · Cited by 350
Elmezayen, A. D., Al-Obaidi, A., Şahin, A. T., & Yelekçi, K. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1758791 · Cited by 350
Ligand Binding Efficiency: Trends, Physical Basis, and Implications
Reynolds, C. H., Tounge, B. A., & Bembenek, S. D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701255b · Cited by 319
A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials
Gayvert, K. M., Madhukar, N. S., & Elemento, O. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.07.023 · Cited by 310
Boobier, S., Hose, D. R. J., Blacker, A. J., & Nguyen, B. N. (2020) · Nature Communications · doi:10.1038/s41467-020-19594-z · Cited by 307
Going further than Lipinski's rule in drug design
Walters, W. P. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.648612 · Cited by 306
alvaDesc: A Tool to Calculate and Analyze Molecular Descriptors and Fingerprints
Mauri, A. (2020) · Methods in Pharmacology and Toxicology · doi:10.1007/978-1-0716-0150-1_32 · Cited by 305
Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer
He, S., Gao, F., Ma, J., Ma, H., Dong, G., & Sheng, C. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202107347 · Cited by 299
A practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
Tallei, T. E., Tumilaar, S. G., Niode, N. J., Fatimawali, Kepel, B. J., Idroes, R., Effendi, Y., Sakib, S. A., & Emran, T. B. (2020) · Scientifica · doi:10.1155/2020/6307457 · Cited by 293
Rescifina, A., Zagni, C., Varrica, M. G., Pistarà, V., & Corsaro, A. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.11.029 · Cited by 274
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271
Shree, P., Mishra, P., Selvaraj, C., Singh, S. K., Chaube, R., Garg, N., & Tripathi, Y. B. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1810778 · Cited by 269
Pandey, P., Rane, J. S., Chatterjee, A., Kumar, A., Khan, R., Prakash, A., & Ray, S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1796811 · Cited by 258
Sanjeevini: a freely accessible web-server for target directed lead molecule discovery
Jayaram, B., Singh, T., Mukherjee, G., Mathur, A., Shekhar, S., & Shekhar, V. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-s17-s7 · Cited by 257
Synthesis of polyheterocycles via multicomponent reactions
Ibarra, I. A., Islas-Jácome, A., & González-Zamora, E. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02305g · Cited by 255
Escribá, P. V., Busquets, X., Inokuchi, J.-I., Balogh, G., Török, Z., Horváth, I., Harwood, J. L., & Vígh, L. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.04.003 · Cited by 252
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Hu, Z., & Crews, C. M. (2022) · ChemBioChem · doi:10.1002/cbic.202100270 · Cited by 231
Ligand efficiency and fragment-based drug discovery
Bembenek, S. D., Tounge, B. A., & Reynolds, C. H. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.007 · Cited by 196
Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?
Dowdy, S. F. (2023) · RNA · doi:10.1261/rna.079507.122 · Cited by 171
Rodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Saha, P., Talukdar, A. D., Nath, R., Sarker, S. D., Nahar, L., Sahu, J., & Choudhury, M. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00509 · Cited by 148
Characteristic roadmap of linker governs the rational design of PROTACs
Dong, Y., Ma, T., Xu, T., Feng, Z., Li, Y., Song, L., Yao, X., Ashby, C. R., & Hao, G.-F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.007 · Cited by 146
Brackman, G., Celen, S., Hillaert, U., Van Calenbergh, S., Cos, P., Maes, L., Nelis, H. J., & Coenye, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016084 · Cited by 136
Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker
Duran-Frigola, M., Pauls, E., Guitart-Pla, O., Bertoni, M., Alcalde, V., Amat, D., Juan-Blanco, T., & Aloy, P. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0502-7 · Cited by 126
Exploring new targets and chemical space with affinity selection-mass spectrometry
Prudent, R., Annis, D. A., Dandliker, P. J., Ortholand, J.-Y., & Roche, D. (2020) · Nature Reviews Chemistry · doi:10.1038/s41570-020-00229-2 · Cited by 104
Coloring Molecules with Explainable Artificial Intelligence for Preclinical Relevance Assessment
Jiménez-Luna, J., Skalic, M., Weskamp, N., & Schneider, G. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01344 · Cited by 96
Antiviral Cyanometabolites—A Review
Mazur-Marzec, H., Cegłowska, M., Konkel, R., & Pyrć, K. (2021) · Biomolecules · doi:10.3390/biom11030474 · Cited by 64
Cierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
Screening-based approaches to identify small molecules that inhibit protein–protein interactions
Choi, S., & Choi, K.-Y. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1280456 · Cited by 29
Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer
Jahid, S., Ortega, J. A., Vuong, L. M., Acquistapace, I. M., Hachey, S. J., Flesher, J. L., La Serra, M. A., Brindani, N., La Sala, G., Manigrasso, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110641 · Cited by 21
Wang, Y., Qin, D., Jin, L., & Liang, G. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105410 · Cited by 19
The comprehensive SARS-CoV-2 ‘hijackome’ knowledge base
Huuskonen, S., Liu, X., Pöhner, I., Redchuk, T., Salokas, K., Lundberg, R., Maljanen, S., Belik, M., Reinholm, A., Kolehmainen, P., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00748-y · Cited by 12
Munawaroh, H. S. H., Gumilar, G. G., Pratiwi, R. N., Khoiriah, S. F., Ningrum, A., Martha, L., Chew, K. W., & Show, P.-L. (2024) · Algal Research · doi:10.1016/j.algal.2024.103468 · Cited by 9
Benzopyrylium salts as new anticancer, antibacterial, and antioxidant agents
Kar, S., Akhir, A., Chopra, S., Ohki, S., Karanam, B., & Golakoti, N. R. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02685-3 · Cited by 8
Hossen, M. A., Jahan, U. M. S., Hossain, M. A., Asif, K. H., Rahman, A., Ahmed, S., Uddin, M. M., Amin, M. F., Barik, M. A., Islam, M. J., et al. (2025) · PLOS One · doi:10.1371/journal.pone.0320550 · Cited by 8
Xu, X., Herdendorf, T. J., Duan, H., Rohlik, D. L., Roy, S., Zhou, H., Alkhateeb, H., Khandelwal, S., Zhou, Q., Li, P., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300630 · Cited by 6
(2024) · doi:10.1007/s00203-024-04140-y · Cited by 2
Metadata
- Authors
- Lipinski, C. A.
- Venue
- Drug Discovery Today: Technologies
- Publisher
- Elsevier BV
- Published
- 2004-12
- Volume
- 1
- Issue
- 4
- Pages
- 337-341
- ISSN
- 1740-6749 (ISSN-L)
- OpenAlex
- W1981737096
- Cited by
- 6,199
- References
- 40
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.